DDInter949 DDInter1840
Human Interferon gamma-1b (140 residues), produced from E. coli. Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein. Purification of the product is achieved by conventional column chromatography. The sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b.
Trabectedin, also referred as ET-743 during its development, is a marine-derived antitumor agent discovered in the Carribean tunicate _Ecteinascidia turbinata_ and now produced synthetically. Trabectedin has a unique mechanism of action. It binds to the minor groove of DNA interfering with cell division and genetic transcription processes and DNA repair machinery. It is approved for use in Europe, Russia and South Korea for the treatment of advanced soft tissue sarcoma. It is currently under evaluation for the treatment of breast cancer, prostate cancer, in addition to pediatric sarcomas. Both the European Commission and the U.S. Food and Drug Administration (FDA) have approved trabectedin as an orphan drug in soft tissue sarcomas and ovarian cancer. On October 23, 2015, the FDA approved trabectedin, (as Yondelis), for the treatment of specific soft tissue sarcomas.
Interferon gamma-1b {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Tioguanine
Tioguanine {u} (Compound) causes {v} (Side Effect) Hepatomegaly
Hepatomegaly {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Interferon gamma-1b {u} may cause a moderate interaction that could exacerbate diseases when taken with {v} Warfarin
Warfarin {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Interferon gamma-1b {u} may lead to a major life threatening interaction when taken with {v} Cladribine
Cladribine {u} (Compound) causes {v} (Side Effect) Haemoglobin
Haemoglobin {u} (Side Effect) is caused by {v} (Compound) Trabectedin
Interferon gamma-1b {u} may lead to a major life threatening interaction when taken with {v} Leflunomide
Leflunomide {u} (Compound) binds {v} (Gene) CYP2C9
CYP2C9 {u} (Gene) is bound by {v} (Compound) Trabectedin
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Tioguanine and Tioguanine (Compound) causes Hepatomegaly (Side Effect) and Hepatomegaly (Side Effect) is caused by Trabectedin (Compound)
Interferon gamma-1b may cause a moderate interaction that could exacerbate diseases when taken with Warfarin and Warfarin (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)
Interferon gamma-1b may lead to a major life threatening interaction when taken with Cladribine and Cladribine (Compound) causes Haemoglobin (Side Effect) and Haemoglobin (Side Effect) is caused by Trabectedin (Compound)
Interferon gamma-1b may lead to a major life threatening interaction when taken with Leflunomide and Leflunomide (Compound) binds CYP2C9 (Gene) and CYP2C9 (Gene) is bound by Trabectedin (Compound)